Sanofi, Denali Drug Fails In ALS, Adding To RIPK1 Program Setbacks

Phase II Trial In Multiple Sclerosis Ongoing

 
• By Mandy Jackson
  
Question mark made by white pills spilling out of brown glass bottle on pink background
It remains to be seen if RIPK1 inhibition will succeed in the clinic • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from R&D